Ramez N. Eskander, MD

Ramez N. Eskander, MD, discusses the limitations of biomarker analyses for guiding treatment decisions in pMMR endometrial cancer.

Experts from across oncology specialties discuss the long-term effects of the COVID-19 pandemic on patient care.

Ramez N. Eskander, MD, discusses the key efficacy findings and future implications of the NIVEC trial of nivolumab in resectable dMMR endometrial cancer.

Ramez N. Eskander, MD, discusses overall survival data for pembrolizumab plus chemotherapy in advanced/recurrent endometrial cancer.

Closing their conversation, Ramez Eskander, MD, and Krishnansu Tewari, MD, share how they envision the future treatment landscape for patients with advanced endometrial cancer.

Key opinion leaders discuss targeted treatment regimens for advanced or recurrent endometrial cancer that are currently under development.

Krishnansu Tewari, MD, presents the profile of a 68-year-old postmenopausal woman with recurrent endometrial cancer for discussion.

Experts explain how they change their treatment strategies if a patient with advanced endometrial cancer does not respond to treatment or experiences disease progression.

Krishnansu Tewari, MD, reviews emerging data from two studies investigating immunotherapy-based combination regimens for the first-line treatment of advanced endometrial cancer.

Krishnansu Tewari, MD, details the first-line treatment options for patients with recurrent endometrial cancer.

Ramez Eskander, MD, presents the profile of a 64-year-old postmenopausal woman diagnosed with recurrent endometrial carcinoma for discussion.

Ramez Eskander, MD, and Krishnansu Tewari, MD, provide an overview of endometrial cancer, including prevalence, staging criteria, and molecular profiling.

Ramez N. Eskander, MD, discusses findings from the phase 3 NRG GY018 trial of pembrolizumab plus chemotherapy in patients with endometrial cancer.

Experts highlight key ongoing trials and emerging therapies for patients with endometrial cancer.

Shared insight on the management of commonly observed adverse events in patients with endometrial cancer who are receiving combination lenvatinib/pembrolizumab.

A brief review of treatment interruption, discontinuation, and dose modification rates in patients receiving combination lenvatinib/pembrolizumab in the KEYNOTE-775 trial or in the experts’ clinical practice.

Vicky Makker, MD, leads a discussion of efficacy data from the KEYNOTE-775 trial on combination lenvatinib/pembrolizumab in patients with endometrial cancer.

A comprehensive overview of first-line treatment options for patients with advanced endometrial cancer.

Experts discuss how molecular testing can inform treatment selection and patient management for those with endometrial cancer.

Vicky Makker, MD and Ramez Eskander, MD discuss the increasing global incidence of endometrial cancer.

Ramez N. Eskander, MD, discusses the utility of lymphadenectomy in patients with endometrial cancer.

Ramez N. Eskander, MD, assistant clinical professor, Department of Reproductive Medicine, University of California, San Diego Moores Cancer Center, discusses the need for more effective biomarkers in the treatment of patients with ovarian cancer.

Ramez N. Eskander, MD, assistant clinical professor, Department of Reproductive Medicine, University of California, San Diego Moores Cancer Center, discusses combination approaches with immunotherapy in ovarian cancer.